LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. It operates through the following segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support (ACS). The Cardiopulmonary segment is involved in the design, development, manufacture, marketing and selling of cardiopulmonary products. The Neuromodulation segment is associated in the design, development, manufacture, marketing and selling of devices that deliver neuromodulation therapy for treating DRE and DTD. The ACS segment deals with the design, development, manufacture, marketing and selling of temporary life support products. The company was founded in 1987 and is headquartered in London, the United Kingdom.
相关临床试验
4
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
1
25.0%
已完成
1
25.0%
招募中
2
50.0%
暂无批准数据
- The RECOVER trial enrolled 493 patients with severe treatment-resistant depression who had failed an average of 13 prior treatments and lived with depression for a mean of 29 years. - At 12 months, 69% of patients receiving active VNS showed meaningful improvement, and over 80% of responders maintained or improved their benefits at 24 months. - Among patients with the strongest 12-month response (≥50% symptom reduction), 92% were still showing benefit at two years, with one in five patients effectively free of depressive symptoms. - Roughly one-third of patients who showed no meaningful benefit at 12 months went on to improve by 24 months, suggesting VNS may have a delayed onset in some individuals.
- The FDA granted premarket approval for LivaNova's aura6000 System, the first hypoglossal nerve stimulation device approved without contraindications related to complete concentric collapse. - The OSPREY randomized controlled trial demonstrated that 65% of patients achieved responder criteria at 12 months, with median apnea-hypopnea index decreasing from 34.3 to 11.0 events per hour. - The proximal hypoglossal nerve stimulation therapy uses six electrodes to provide customizable treatment options for moderate to severe obstructive sleep apnea patients. - LivaNova is developing a next-generation device with MRI compatibility and 15-year battery life, anticipated for release in the first half of 2027.
- LivaNova PLC has launched its Essenz Perfusion System in China after receiving regulatory approval from the National Medical Products Administration, targeting the world's second-largest heart-lung machine market. - The next-generation cardiopulmonary platform has supported over 100,000 patients globally since its 2023 launch and offers real-time monitoring with patient-tailored perfusion capabilities. - China represents a significant growth opportunity with 330 million individuals affected by cardiovascular disease and over 700 hospitals equipped for cardiac surgery. - The system addresses the projected 185,000 adult and 23,500 pediatric extracorporeal circulation procedures expected in China for 2025.
